Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | PPARA | Q07869 | 11/20 | 0.32 |
| ▸ | PPARG | P37231 | 8/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | PPARD | Q03181 | 11/20 | 0.32 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.32 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.31 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.31 |
| ▸ | MCTS1 | Q9ULC4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3601093 | 0.83 | L3MBTL1 (0.39) | TDP1L3MBTL1ALDH1A1MEN1KMT2A | |
| SCHEMBL3601746 | 0.82 | ALDH1A1 (0.37) | TDP1L3MBTL1ALDH1A1MEN1KMT2A | |
| SCHEMBL3615618 | 0.82 | ALDH1A1 (0.37) | TDP1L3MBTL1ALDH1A1MEN1KMT2A | |
| SCHEMBL3611899 | 0.81 | TDP1 (0.35) | TDP1L3MBTL1ALDH1A1MEN1KMT2A | |
| SCHEMBL3596945 | 0.77 | TDP1 (0.41) | TDP1L3MBTL1ALDH1A1MEN1KMT2A | |
| SCHEMBL3610769 | 0.76 | SMN1; SMN2 (0.35) | TDP1L3MBTL1ALDH1A1LMNA | |
| SCHEMBL3602949 | 0.71 | PTGDR2 (0.35) | TDP1L3MBTL1ALDH1A1MEN1KMT2A | |
| SCHEMBL3605174 | 0.68 | ALDH1A1 (0.40) | TDP1ALDH1A1KMT2APPARGLMNA | |
| SCHEMBL5157805 | 0.67 | PPARA (0.50) | TDP1L3MBTL1ALDH1A1MEN1KMT2A | |
| SCHEMBL3609770 | 0.66 | SMN1; SMN2 (0.37) | L3MBTL1PPARAPPARGPPARDSLC16A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016396-A1 | PYRAZOLE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-21 | — | — | US | disclosed |
| EP-2128138-A1 | PYRAZOLE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016396-A1 | PYRAZOLE COMPOUND | SLC5A1, SLC5A2, GLP1R | TDP1 2502/4885L3MBTL1 3563/4885ALDH1A1 365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.